Wall Street analysts predict that Pfizer Inc. (NYSE:PFE) will announce $12.90 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Pfizer’s earnings. The lowest sales estimate is $12.83 billion and the highest is $12.97 billion. Pfizer posted sales of $12.78 billion in the same quarter last year, which suggests a positive year over year growth rate of 0.9%. The business is expected to report its next earnings report on Tuesday, May 1st.
On average, analysts expect that Pfizer will report full-year sales of $12.90 billion for the current fiscal year, with estimates ranging from $54.02 billion to $54.69 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $54.77 billion per share, with estimates ranging from $54.32 billion to $55.26 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Pfizer.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same period last year, the business earned $0.47 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Shine Investment Advisory Services Inc. bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $103,000. First Dallas Securities Inc. bought a new stake in shares of Pfizer in the 4th quarter worth approximately $118,000. Herndon Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $120,000. Finally, Americafirst Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $127,000. 70.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Pfizer (NYSE PFE) opened at $34.66 on Tuesday. Pfizer has a one year low of $31.67 and a one year high of $39.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market capitalization of $203,617.75, a PE ratio of 9.87, a PEG ratio of 1.93 and a beta of 0.94.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.92%. Pfizer’s dividend payout ratio is currently 38.75%.
Pfizer declared that its Board of Directors has approved a share buyback plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.